A Tiny Upstart Takes Aim at Robotic Surgery

A Tiny Upstart Takes Aim at Robotic Surgery

Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX)  Senhance. Senhance is a robotic system that assists surgeons performing laparoscopic surgeries. It offers advantages, including haptic feedback, that could differentiate it from Intuitive Surgical's da Vinci system. Will TransEnterix carve out a meaningful slice of this fast-growing market?

Intuitive Surgical's ground-breaking da Vinci systems are reshaping laparoscopic surgery.

IMAGE SOURCE: TRANSENTERIX.

Continue reading

Source: Fool.com